Cerus
CERS----
Cerus (CERS)
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood s...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Cerus Analyst Rating
View MoreForecast & Rating
Jun 9, 2026Price forecast
$4.6759.27%
Forecast & RatingStrong buy
3analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Jul 20 at 04:04 PM
Cerus CEO Vivek K. Jayaraman disposes of 16,666 common shares worth $52,665.56
- Market Beat · Jul 17 at 10:40 AM
Cerus Corporation (NASDAQ:CERS) Short Interest Down 35.3% in June
- PUBT · Jul 10 at 03:36 PM
Cerus names William “Obi” Greenman executive chairman after CEO exit
- PUBT · Jun 17 at 07:30 AM
Cerus showcases INTERCEPT Blood System evidence at ISBT Congress
- Market Beat · Jun 14 at 03:18 AM
Cerus Corporation (NASDAQ:CERS) Sees Significant Decrease in Short Interest
- benzinga_article · Jun 10 at 09:43 PM
Cathie Wood Sells Robinhood Stock, Doubles Down On This George Soros-Backed AI Stock
